Long Term Follow-up Grafted Huntington's Disease Patients

The aim is to create a specific cohort of transplant patients, to homogenise their follow-up methods, to collect all the patient data (medical, paramedical, imaging, biological) acquired from the end of their participation in MIG-HD'study (Foetal Striatal allografting in Huntington's disease: a multicentre, randomised, delayed start, phase 2 open-label cell therapy trial) until the last possible follow-up of the last patient in the study

• Slopes comparison of neurological scores (Unified Huntington's Disease Rating Scale (UHDRS) or Unified Huntington's Disease Rating Scale For Advanced Patients (UHDRS-FAP)) before and after transplantation [Time frame: From the end of participation at MIGHD's study until the death from any cause or assessed up to 10 years after consentement signed]
• Slopes comparison of cognitive scores (Unified Huntington's Disease Rating Scale (UHDRS) or Unified Huntington's Disease Rating Scale For Advanced Patients (UHDRS-FAP)) before and after transplantation [Time frame: From the end of participation at MIGHD's study until the death from any cause or assessed up to 10 years after consentement signed]
• Slopes comparison of psychiatric scores (Unified Huntington's Disease Rating Scale (UHDRS) or Unified Huntington's Disease Rating Scale For Advanced Patients (UHDRS-FAP)) before and after transplantation [Time frame: From the end of participation at MIGHD's study until the death from any cause or assessed up to 10 years after consentement signed]
• Slopes comparison of neuropsychologic scores (Mattis Dementia Rating Scale/Trail Making test/Hopkins Verbal Learning Test/Categorical fluency/Sign barrier test/Montgomery-Åsberg Depression Rating Scale (MADRS)) before and after transplantation [Time frame: From the end of participation at MIGHD's study until the death from any cause or assessed up to 10 years after consentement signed]
• Comparison of the clinical evolution (Unified Huntington's Disease Rating Scale (UHDRS) or Unified Huntington's Disease Rating Scale For Advanced Patients (UHDRS-FAP)) of transplanted patients with that of non-transplanted patients in the BioHD cohort [Time frame: From the end of participation at MIGHD's study until the death from any cause or assessed up to 10 years after consentement signed]
• Events and adverse reactions recording since the transplantation [Time frame: From the end of participation at MIGHD's study until the death from any cause or assessed up to 10 years after consentement signed]
• Research and identification of anti-MHC Ab from samples acquired under the MIG-HD and Post-MIGHD protocols as well as in care [Time frame: From the end of participation at MIGHD's study until the death from any cause or assessed up to 10 years after consentement signed]
• Correlation between graft activity measured by imaging and patient performance [Time frame: From the end of participation at MIGHD's study until the death from any cause or assessed up to 10 years after consentement signed]
• Correlation between post-mortem observations of the brains of deceased patients and measurements obtained by MRI and PET-SCAN in studies MIG-HD and BioHD [Time frame: From the end of participation at MIGHD's study until the death from any cause or assessed up to 10 years after consentement signed]
• Correlation between post-mortem brain observations and patient performance before death [Time frame: From the end of participation at MIGHD's study until the death from any cause or assessed up to 10 years after consentement signed]
• Analysis of brains collected as part of MIG-HD and POST-MIGHD i) to quantify neuropathological lesions ii) to search for markers of inflammatory reactions [Time frame: From the end of participation at MIGHD's study until the death from any cause or assessed up to 10 years after consentement signed]
• Research into predictive factors (relationships between fetal haplotypes, patient haplotypes and appearance of alloimmunization phenomena) of the evolution of transplanted patients [Time frame: From the end of participation at MIGHD's study until the death from any cause or assessed up to 10 years after consentement signed]